Introduction
Basal cell carcinoma (BCC) constitutes approximately 80% of non-melanoma skin cancers and is the most commonly diagnosed cancer worldwide [1, 2] . Although most BCCs are curable by surgery, disease may progress to advanced BCC (locally advanced/metastatic BCC), for which radiotherapy and surgery are inappropriate because cure is unlikely and/or because surgery might result in substantial deformity [3, 4] .
The key molecular driver in the development of BCC is abnormal Hedgehog pathway signalling, exhibited in >90% of BCCs [5] . Vismodegib is a first-in-class inhibitor of the Hedgehog signalling pathway.
Vismodegib is approved (by the US Food and Drug
Administration [FDA] and the European Medicines Agency [EMA]) [6, 7] for the treatment of adults with metastatic BCC or with locally advanced BCC that is inappropriate for surgery or radiotherapy. The pivotal phase II study ERIVANCE BCC demonstrated vismodegib response rates of 43% and 30% in patients with locally advanced and metastatic BCC, respectively, by independent review [8] . Subsequent analyses from ERIVANCE BCC demonstrated durable responses and a consistent efficacy/safety profile [9, 10] . The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665) assesses safety and efficacy of vismodegib in a setting representative of clinical practice, and it is the largest study ever conducted in patients with BCC [11] . We report results from the primary analysis of the total evaluable population (N Z 1215, data cut-off March 16, 2015).
Methods

Study design and patients
STEVIE is a single-arm, multicentre, open-label study involving 167 sites in 36 countries. The study design was previously published [11] . Eligible patients (18 years old) had a histologically confirmed diagnosis of locally advanced/metastatic BCC, Eastern Cooperative Oncology Group (ECOG) performance status of 0e2, and adequate organ function. For patients with locally advanced BCC, the lesion was deemed inoperable/ inappropriate for surgery, and radiotherapy must have been previously administered, unless inappropriate. Patients with measurable and/or non-measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, were eligible for enrolment. Patients with Gorlin syndrome who met inclusion criteria were also enrolled.
The study protocol was approved by the institutional review boards or independent ethics committees of participating centres, and the study was undertaken in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Patient safety was monitored by an independent data safety monitoring board (DSMB) that reviewed all aspects of safety, including death. All patients provided written informed consent.
Enrolled patients received oral vismodegib 150 mg/d continuously until disease progression, unacceptable toxicity, withdrawal of consent, death or other reasons for discontinuation. Dose reductions were not allowed; however, treatment interruption of up to 8 weeks was permitted for management of toxicity or temporary inability to swallow capsules.
Primary end-point was safety. Assessments included treatment-emergent adverse events (TEAEs, defined as occurring between the first administration and 30 days after the last administration of study drug [inclusive] and assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 4.0), limited physical examination, vital signs, ECOG performance status and laboratory parameters. Patients enrolled after approval of study protocol version 2 had five safety follow-up visits at 1, 3, 6, 9 and 12 months after the last dose of vismodegib to assess resolution of TEAEs ongoing at the time of treatment discontinuation and progression-free survival (PFS). Secondary end-points included investigator-assessed objective response according to RECIST v1. 1 Tumour assessment by physical examination was performed every 4e8 weeks. When necessary, computed tomography (CT) and magnetic resonance imaging (MRI) were performed every 8e16 weeks.
Statistical analysis
The sample size was selected to allow the adverse event (AE) incidence rate to be estimated within 1.6% and 1.8% of the true AE rate, assuming an observed incidence of 10% (i.e. within a 95% Clopper-Pearson confidence interval [CI] of 8.4e11.8) and with a precision to estimate an AE of 1% frequency to within 0.5% and 1% of the true AE rate.
The efficacy-evaluable population included all patients who received at least one dose of study drug and had histologically confirmed disease at baseline (used for PFS and OS analysis). Patients who also had measurable disease at baseline were included in best overall response rate (BORR) and TTR assessments. All timeto-event end-points were analysed using the KaplaneMeier method; 95% CIs were calculated using the Brookmeyer and Crowley method.
Results
Patient demographics and characteristics
Between June 2011 and September 2014, 1232 patients were enrolled in STEVIE at 167 sites in 36 countries. Seventeen patients were excluded from the safety and efficacy analysis (no documented exposure based on return of drug dispensed), leaving 1215 evaluable patients (1119 locally advanced, 96 metastatic BCC; Supplementary  Fig. S1 ). Table 1 shows baseline characteristics. At the time of clinical cut-off, 147 patients (12%) were receiving treatment with vismodegib. TEAEs were the main reason for treatment discontinuation (n Z 349).
Safety
Most patients (1192 [98%]) had 1 TEAE on study; the most common (>20% incidence) TEAEs Table S5 ). The DSMB determined these cases to be unrelated to vismodegib (n Z 6) or not assessable because of insufficient clinical data (n Z 1).
The TEAEs leading to treatment discontinuation reported in 380 patients (31%) were primarily grade 1/2. The most frequently reported TEAEs were muscle Further evaluation of STEVIE showed that 51 patients (4%) with advanced BCC experienced cutaneous squamous cell carcinoma (SCC). Most patients were aged >75 years with lesions located in sun-exposed areas; 18 patients (35%) had a history of cutaneous SCC, three patients (6%) had a history of Bowen disease, and two patients (4%) had a history of actinic keratosis.
Due to the prevalence of muscle spasm in patients taking Hedgehog pathway inhibitors (HPIs), additional assessment of blood creatine phosphokinase (CPK) levels was performed. The TEAE of increased blood CPK was reported in 60 patients (4.9%) (Supplementary Table S1 ). The exploratory analysis used quantitative laboratory data from patients for whom 1 CPK measurement was available during the treatment period and showed CPK elevations in 36.4% of patients who did not experience muscle spasm and 33.9% of patients who did experience muscle spasm (Supplementary Fig. S2 and Supplementary Table S6 ).
An exploratory analysis of AE reversibility after treatment discontinuation included 266 patients who completed their 12-month follow-up. At the time of treatment discontinuation, 97% of patients had 1 ongoing AE. This decreased during the post-treatment phase, with 92.5%, 74.8%, 59.0%, 48.9% and 45.5% of patients having ongoing AEs at 1, 3, 6, 9 and 12 months after treatment, respectively ( Supplementary Fig. S3 ). Analysis of the five most common TEAEs associated with vismodegib treatmentdmuscle spasm, alopecia, ageusia, dysgeusia and decreased weightdin Gorlin syndrome and non-Gorlin syndrome patient subgroups also showed a reduction in the proportion of patients with ongoing AEs during the post-treatment period (Supplementary Table S7 ). Most instances of muscle spasm resolved 1e3 months after treatment, and most occurrences of ageusia, dysgeusia and alopecia resolved by 6 months after treatment. Events of weight decreased took slightly longer to resolve; most patients experienced resolution by 12 months after treatment. There were no differences in TEAE resolution between patients with Gorlin syndrome and those without, and the pattern of resolution over time in the two subgroups was similar to that seen in the overall population. A number of patients began receiving commercial vismodegib at the 12-month follow-up visit (four patients with muscle spasms; six patients with alopecia; two patients with ageusia, five patients with dysgeusia and seven patients with weight decreased), confounding interpretability. After patients taking commercial vismodegib were excluded, the prevalence of ongoing AEs was 3.4% for muscle spasm, 8.1% for alopecia, 1.5% for ageusia, 3.4% for dysgeusia and 5.4% for weight decreased. Additional medical review of these ongoing cases showed that most were grade 1 and many of the patients with grade 2/3 AEs also had medical history/risk factors in addition to age that confounded the assessment of the AEs and attribution of the AEs to vismodegib treatment.
Efficacy
Median follow-up was 17.9 months, and 1161 patients in the efficacy-evaluable population had histologically confirmed measurable disease. Response rates were 68.5% (95% CI 65.7e71.3) in patients with locally advanced BCC and 36.9% (95% CI 26.6e48.1) in patients with metastatic BCC (Table 3) , including CR in 33.4% and 4.8% of patients with locally advanced and metastatic BCC, respectively. Other end-points are described in Table 3 and Supplementary Fig. S4 . OS data for patients in the efficacy-evaluable population (both cohorts) are immature; therefore, median OS was not estimable. Response rates in patients with Gorlin CPK Z creatine phosphokinase; GGT Z gamma-glutamyl transferase; TEAE Z treatment-emergent adverse event.
For each preferred term, the total number of TEAEs occurring at a rate of at least 10 events per 100 patienteyears is displayed. No grade 3 TEAEs occurred at 10 events per 100 patienteyears. The most common grade 3 TEAEs in either time period were muscle spasm, weight decreased, GGT increased, hypertension, dysgeusia, asthenia, fatigue and blood CPK level increased. A patient can be counted in both exposure categories if their total duration is 12 months or more. TEAEs were defined as occurring between the first administration of study drug and 30 days after the last administration of study drug, inclusive.
syndrome and histologically confirmed measurable disease were 81.7% (95% CI 75.8e86.7) and 80.0% (95% CI 28.4e99.5) in patients with locally advanced and metastatic BCC, respectively (Table 4 ).
Discussion
The STEVIE patient population is analogous to the real-world setting of advanced BCC because patients were elderly (median 72.0 years in locally advanced BCC) with a high level of comorbidities (91.7%) at baseline. A disease registry evaluating real-world practice in the United States (RegiSONIC study) supports similarities between the STEVIE population and patients treated in routine medical practice, reporting a median age of newly diagnosed patients with locally advanced BCC of 68 years [12] . Epidemiology studies in metastatic BCC have demonstrated a higher predominance of metastatic BCC in males (69%) similar to that in STEVIE (63%) and a similar pattern of disease spread; the most common sites are lymph nodes, lung and bone [13] . The primary analysis results demonstrate a consistent safety profile with that previously reported for vismodegib in patients with advanced BCC [8e11].
Commonly occurring AEs are similar to those seen with other HPIs; most patients experience muscle spasm, alopecia and taste disturbances (ageusia/dysgeusia) [11, 14] . Although muscle-related AEs such as muscle spasm are seen with all HPIs, increases in CPK level in Table 4 Best confirmed overall response rate in patients with histologically confirmed and measurable disease by Gorlin syndrome status.
Efficacy parameter
Locally [14] . There were no reports of rhabdomyolysis in STEVIE. Exploratory analysis did not demonstrate any association between CPK abnormalities and muscle spasm or any clinically relevant sequelae, including renal insufficiency. As experience with HPIs has increased, questions have arisen regarding the development of cutaneous SCC after exposure to vismodegib and the persistence of AEs after drug discontinuation [15, 16] . Data from this large patient population with advanced BCC provide further understanding regarding these events, such as prevalence and risk factors.
The causality assessment in SCC is challenging because the observation occurred in a single-arm study and there is a known increased risk for developing new SCCs in patients with a history of BCC [17, 18] . However, the incidence of cutaneous SCC in STEVIE was 4.2%, in contrast with the 12.5% observed in ERIV-ANCE BCC and consistent with the expected incidence based on literature in a similar population [19] . A recent meta-analysis estimating the risk for subsequent SCC in patients with a history of BCC reported a pooled estimate proportion of 4.3% (95% CI 1.7e10.1%) [18] . Nevertheless, the current analysis is limited by the lack of histological data and a control arm in STEVIE.
Case reports of persistent AEs have been described with vismodegib treatment [19] . STEVIE showed that the majority of common AEs associated with vismodegib treatment (muscle spasm, alopecia, ageusia, dysgeusia and decreased weight) that were ongoing at the time of treatment discontinuation resolved by 12 months after treatment discontinuation. The remaining cases were mostly mild, and confounding factors were present in all cases. The presence of ongoing AEs >6 months after treatment discontinuation might be related to the persistent blood levels of vismodegib due to the long half-life of this protein-bound drug, or it may be related to the physiological process associated with the AE (e.g. the kinetics of the hair growth cycle).
In the current study, most TEAEs that led to treatment discontinuation were grade 1/2, and 147 patients remain on treatment at the time of this report, demonstrating that the chronicity of AEs rather than the severity can lead to discontinuation. Management of TEAEs is essential to optimise treatment benefit; educating patients on what to expect and possible management options is important. Management recommendations that provide guidance for healthcare professionals have been published [20e23] , and physicians should consult their local prescribing information for guidance on management of TEAEs.
Efficacy in this analysis was consistent with the previously reported efficacy profile of vismodegib in advanced BCC [10, 11] . Response rates of 68.5% and 36.9% in patients with locally advanced and metastatic BCC, respectively, in STEVIE are consistent with those reported by investigators in ERIVANCE BCC at the final (30-month) analysis (60.3% and 48.5%), respectively [10] ; DOR and PFS were also consistent with those of the final analysis of ERIVANCE BCC. The Gorlin subgroup analysis indicates that patients with Gorlin syndrome responded better to treatment, with a considerably higher rate of CR (45.1%) than patients without Gorlin syndrome (28.2%), which might be a result of these patients being younger and having a better ECOG performance status than patients without Gorlin syndrome. However, it is clear that response rates in the whole study population were not influenced by the inclusion of patients with Gorlin syndrome because they were similar to response rates in the subgroup of patients without Gorlin syndrome.
Limitations of STEVIE include the absence of a control arm and the lack of independent central review [8] ; however, the STEVIE population is reflective of real-world patients seen in everyday practice. A multidisciplinary approach is essential to the decision to treat patients with advanced BCC with use of HPIs. Close follow-up of patients after treatment initiation is necessary to manage TEAEs and assess continued benefit of treatment.
Results from the primary analysis of STEVIE show that vismodegib has a manageable and consistent safety profile in a population representative of patients treated in routine clinical practice. Treatment with vismodegib led to tumour response and control and should be considered for this difficult-to-treat patient group.
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